Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.

ABCs in Dermatology: Previewing the 2026 AAD Annual Meeting

In this Q&A, Linda Stein Gold, MD, shares her views on the clinical significance of icotrokinra's FDA approval and the data leading to this approval.

Q&A: Research Leading to FDA Approval of Icotrokinra for Psoriasis, With Linda Stein Gold, MD

After the oral IL-23 inhibitor icotrokinra's (Icotyde) FDA approval, this interview covers what primary care clinicians should conclude.


Takeaways on Icotrokinra and Psoriasis for Clinicians, With Linda Stein Gold, MD

Linda Stein Gold, MD, shares her perspective on the clinical significance of icotrokinra's FDA approval and what dermatologists need to know.

Key Points on Icotrokinra Following FDA Approval for Psoriasis, With Linda Stein Gold, MD

This preview highlights key data to watch out for during the 2026 American Academy of Dermatology (AAD) meeting in Denver, Colorado.

AAD 2026 Preview: Late Breaking Data to Watch

FDA clears once-daily icotrokinra for moderate-to-severe plaque psoriasis in adults and teens.

Icotrokinra, an Oral Il-23 Inhibitor, Receives FDA Approval for Psoriasis

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

HCPLive 5 Stories in Under 5: Week of 03/08

This segment of Bhatia's interview highlights imsidolimab's reported durability of response for those with generalized pustular psoriasis (GPP).

Discussing the Significance of Imsidolimab’s Rate of Response in GPP, With Neal Bhatia, MD

This interview highlights the significance of the potential FDA approval of imsidolimab for patients with generalized pustular psoriasis (GPP).

What Is the Significance of New Data on Imsidolimab for GPP? With Neal Bhatia, MD

This Q&A with Neal Bhatia, MD, features a discussion conducted regarding GLP-1 use in patients with psoriasis and obesity or overweight.

Q&A on Treating Psoriasis, Obesity with Tirzepatide and Ixekizumab, With Neal Bhatia, MD

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis